GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Debt-to-Revenue

Kyorin Pharmaceutical Co (TSE:4569) Debt-to-Revenue : 0.23 (As of Sep. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Kyorin Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was 円10,300 Mil. Kyorin Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was 円14,335 Mil. Kyorin Pharmaceutical Co's annualized Revenue for the quarter that ended in Sep. 2024 was 円106,880 Mil. Kyorin Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.23.


Kyorin Pharmaceutical Co Debt-to-Revenue Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Debt-to-Revenue Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.21 0.21 0.19 0.18

Kyorin Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.16 0.16 - 0.23

Competitive Comparison of Kyorin Pharmaceutical Co's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Debt-to-Revenue falls into.


;
;

Kyorin Pharmaceutical Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Kyorin Pharmaceutical Co's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(20387 + 559) / 119532
=0.18

Kyorin Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(10300 + 14335) / 106880
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Kyorin Pharmaceutical Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co Headlines

No Headlines